The state of California currently has 20 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/09/2024
Locations: Keck School of Medicine of USC, Los Angeles, California
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
NCT06331624
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
03/19/2024
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
NCT05180162
Recruiting
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: UCSF Fresno, Fresno, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/02/2024
Locations: UCSF Parnassus, San Francisco, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT05954988
Recruiting
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Gender:
All
Ages:
40 years and above
Trial Updated:
08/29/2023
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
NCT03183570
Recruiting
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2023
Locations: Stanford University, Stanford, California
Conditions: Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Register for Updates
Atezolizumab for Idiopathic Pulmonary Fibrosis
NCT05515627
Recruiting
The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/19/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates